沃森生物(300142.SZ)一季度預盈2860萬-3400萬元 同比扭虧為盈
格隆匯 4 月 8日丨沃森生物(300142.SZ)公佈,預計2021年第一季度歸屬於上市公司股東的淨利潤2860萬元-3400萬元,上年同期虧損1811.77萬元;扣除非經常性損益後的淨利潤7360萬元-7900萬元。
報吿期,公司疫苗產品較上年同期新增13價肺炎球菌多糖結合疫苗銷售致公司疫苗產品銷售量和銷售收入同比增加,歸屬於上市公司股東的淨利潤較去年同期增長。
報吿期,公司加大新產品、新項目研發投入,研發費用較上年同期增加。另外,因公司持有的JH BP (CY) Holdings Limited股權資產的股票價格本報吿期未較期初下跌形成公允價值變動損失,影響公司歸屬於上市公司股東的淨利潤。
報吿期,公司預計非經常性損益影響歸屬於上市公司股東的淨利潤約-4400萬元,上年同期為178.35萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.